Regeneron and bluebird bio enter cell therapy pact; Collaboration expanded
Regeneron Pharmaceuticals Inc. and bluebird bio Inc. will lean on each other’s platform discoveries to together discover and develop antibodies and T-cell receptors directed against tumor-specific proteins and peptides.
- Gene Therapy, Cell Therapy
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.